Human Molecular Genetics Advance Access originally published online on September 26, 2007
Human Molecular Genetics 2007 16(24):3117-3127; doi:10.1093/hmg/ddm273
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma
1 Durkan Leukaemia Laboratories, Department of Haematology, 2 Neuropsychiatric Genetics Research Group, Department of Psychiatry, Institute of Molecular Medicine, Trinity College Dublin, Ireland, 3 School of Public Health and Population Science, University College Dublin, Ireland, 4 Divison of Epidemiology, German Cancer Research Center, Heidelberg, Germany, 5 Epidemiology, Municipal Institute of Medical Research, Barcelona, Spain, 6 Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic, 7 Unit of Biological Haematology, Dijon University Hospital, Dijon, France, 8 Institute of Occupational Medicine, University of Cagliari, Cagliari, Italy, 9 International Agency for Research on Cancer, Lyon, France and 10 Core Genotyping Facility, Advanced Technology Corp., National Cancer Institute Gaithersburg, MD NIH, USA
* To whom correspondence should be addressed at: Durkan Leukaemia Laboratories, Institute of Molecular Medicine, Trinity Centre, St James’s Hospital, Dublin 8, Ireland. Tel: +353 1 896 2093; Fax: +353 1 410 3476; Email: mplawler{at}tcd.ie, mlawler{at}stjames.ie (Mark Lawler).
Received July 17, 2007; Accepted September 14, 2007
Cytogenetic analysis in myeloma reveals marked chromosomal instability. Both widespread genomic alterations and evidence of aberrant class switch recombination, the physiological process that regulates maturation of the antibody response, implicate the DNA repair pathway in disease pathogenesis. We therefore assessed 27 SNPs in three genes (XRCC3, XRCC4 and XRCC5) central to DNA repair in patients with myeloma and controls from the EpiLymph study and from an Irish hospital registry (n = 306 cases, 263 controls). For the haplotype-tagging SNP (htSNP) rs963248 in XRCC4, Allele A was significantly more frequent in cases than in controls (86.4 versus 80.8%; odds ratio 1.51; 95% confidence interval 1.10–2.08; P = 0.0133), as was the AA genotype (74 versus 65%) (P = 0.026). Haplotype analysis was performed using Unphased for rs963248 in combination with additional SNPs in XRCC4. The strongest evidence of association came from the A–T haplotype from rs963248–rs2891980 (P = 0.008). For XRCC5, the genotype GG from rs1051685 was detected in 10 cases from different national populations but in only one control (P = 0.015). This SNP is located in the 3'-UTR of XRCC5. Overall, these data provide support for the hypothesis that common variation in the genes encoding DNA repair proteins contributes to susceptibility to myeloma.
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Tewari, E. Kenny, A. Staines, S. Chanock, P. Browne, and M. Lawler Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide Blood, May 28, 2009; 113(22): 5691 - 5692. [Full Text] [PDF]
|
|